Top 10 Performing Stocks To Watch Right Now

Top 10 Performing Stocks To Watch Right Now: Baxter International Inc. (BAX)

Baxter International Inc., through its subsidiaries, develops, manufactures, and markets products for people with hemophilia, immune disorders, infectious diseases, kidney disease, trauma, and other chronic and acute medical conditions. It operates in three segments: BioScience, Medication Delivery, and Renal. The BioScience segment processes recombinant and plasma-based proteins to treat hemophilia and other bleeding disorders; plasma-based therapies to treat immune deficiencies, alpha 1-antitrypsin deficiency, burns and shock, and other chronic and acute blood-related conditions; products for regenerative medicine, such as biosurgery products; and vaccines. The Medication Delivery segment manufactures intravenous solutions and administration sets; premixed drugs and drug-reconstitution systems; pre-filled vials and syringes for injectable drugs; intravenous nutrition products; infusion pumps; and inhalation anesthetics. It also offers products and services related to pha rmacy compounding, drug formulation, and packaging technologies. The Renal segment provides products to treat end-stage renal disease or irreversible kidney failure. It manufactures solutions and other products for peritoneal dialysis, a home-based therapy; and distributes product for hemodialysis, which is conducted in a hospital or clinic. It markets its products to hospitals, kidney dialysis centers, nursing homes, rehabilitation centers, doctors? offices, clinical and medical research laboratories, and patients at home under physician supervision. The company was founded in 1931 and is based in Deerfield, Illinois.

Advisors' Opinion:

• [By ovenerio]

  The company has a current ROE of 15.24% which is higher than the industry median. Also, it is higher than the ones exhibit by Abbott (ABT) and Stryker (SYK). In general, an! alysts consider ROE ratios in the 15-20% range as representing attractive levels for investment. So, for investors looking at those levels, Medtronic and Baxter (BAX) also could be good options. It is very important to understand this metric before investing, and it is important to look at the trend in ROE over time.

• [By Jayson Derrick]

  Pfizer (NYSE: PFE) has agreed to acquire Baxter International's (NYSE: BAX) vaccine business for $635 million. Shares of Pfizer lost 0.71 percent, closing at $29.26 while shares of Baxter International lost 0.33 percent, closing at $76.09.

• [By Holly LaFon]

  Performance data quoted represents past performance and is no guarantee of future results. Current performance may be lower or higher than the performance data quoted. Investment return and principal value will fluctuate so that an investor's shares, when redeemed, may be worth more or less than original cost. As stated in the current prospectus, the Fund's Investor Class Share's annual operating expense ratio (gross) is 1.28%. The Fund's adviser has contractually agreed to waive a portion of its fee and/or reimburse Fund expenses to limit total annual operating expenses at 1.25%, which is in effect until October 31, 2015. Other share classes may vary. The Fund charges a 2.0% redemption fee on shares redeemed within six months of purchase. For the most recent month-end performance, please call (877)328-9437 or visit the Advisor's website at www.auxierasset.com. The recent growth rate in the stock market has helped to produce short-term returns that are not typical and may not continue in the future.Spring 2014 Market CommentaryAuxier Focus Fund's Investor Class returned a modest 0.25% for the quarter ended March 31, while Standard and Poor's 500 Stock Index (S&P) rose 1.81%. The Fund ended the quarter with 70% in U.S. stocks, 16% foreign stocks, 1.7 % bonds and 12.3% cash. Since inception in 1999, the Fund's equity exposure has averaged 72%. O! ur stockh! oldings in the healthcare industry generally gained for the quarter. But many of our multinational and foreign stocks were hurt by the threat of currency repercussions from geopolitical events in Russia and Ukraine. The foreign portion of the Fund is easily the most undervalued. Longer term, we see a very favorable risk/reward potential with our UK and European holdings. Some emerging market companies we follow are the cheapest in over twenty years. In allocating capital, we much prefer the gloom of down to flat markets and the corrective process that tempers exuberance. We re member that one of th

• [By Monica Gerson]

  Baxter International (NYSE: BAX) is expected to report its Q1 earnings at $1.09 per share on revenue of $3.88 billion.

  The Sherwin-Williams Company (NYSE: SHW) is projected to report its Q1 earnings at $1.11 per share on revenue of $2.36 billion.

source from Top Stocks For 2015:http://www.topstocksblog.com/top-10-performing-stocks-to-watch-right-now-2.html